Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma

Biomarkers

Volumn 17, Issue 6, 2012, Pages 539-544

  Idowu, O K ^a   Ding, Q ^a   Taktak, A F G ^b   Chandrasekar, C R ^a   Yin, Q ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarkers sarcoma; Inflammation in cancer; Neutrophil lymphocyte ratio; Sarcoma diagnosis; Soft tissue tumors

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PROPORTIONAL HAZARDS MODEL; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; YOUNG ADULT;

EID: 84865728055     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.699554     Document Type: Article

References (46)

1. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ. (2010). Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516-122.
2. Benassi MS, Magagnoli G, Ponticelli F, Pazzaglia L, Zanella L, Gamberi G, Ragazzini P, Ferrari C, Mercuri M, Picci P. (2003). Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas. Histol Histopathol 18:1035-1040.
3. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton- Jansen AM. (2011). Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents. Clin Cancer Res 17:2110-2119.
4. Bui MM, Han G, Acs G, Reed D, Gonzalez RJ, Pasha TL, Zhang PJ. (2011). Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor. Sarcoma 2011:971050.
5. Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, Rydholm A, Nilbert M. (2011). A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer 117:1279-1287.
6. Clark MA, Fisher C, Judson I, Thomas JM. (2005). Soft-tissue sarcomas in adults. N Engl J Med 353:701-711.
7. Clarke SJ, Chua W, Moore M, Kao S, Phan V, Tan C, Charles K, McMillan DC. (2011). Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Therapeut 90:475-478. DOI: 10.1038/ clpt.2011.122.
8. Coosemans A, Van Calster B, Verbist G, Moerman P, Vergote I, Van Gool SW, Amant F. (2011). Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer 21:302-308.
9. Crago AM, Socci ND, DeCarolis P, O'Connor R, Taylor BS, Qin LX, Antonescu CR, Singer S. (2012). Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res 18:1334-1340.
10. de Nigris F, Zanella L, Cacciatore F, De Chiara A, Fazioli F, Chiappetta G, Apice G, Infante T, Monaco M, Rossiello R, De Rosa G, Alberghini M, Napoli C. (2011). YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma. BMC Cancer 11:472.
11. Fernebro J, Bladstrom A, Rydholm A, Gustafson P, Olsson H, Engellau J, Nilbert M. (2006). Increased risk of malignancies in a populationbased study of 818 soft-tissue sarcoma patients. Br J Cancer 95:986-990.
12. Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, Yamada H, Okada S, Watari K, Ono M, Kuwano M, Kamura S, Iida K, Okada Y, Koga M, Iwamoto Y. (2011). Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 179:1157-1170.
13. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. (2011). The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer 105:93-103.
14. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. (1999). Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 125:577-581.
15. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW, Taubert H. (2012). Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 130:1230-1235.
16. Grimer RJ, Briggs TW. (2010). Earlier diagnosis of bone and soft-tissue tumours. J Bone Joint Surg Br 92:1489-1492.
17. Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. (2010). Extremity soft tissue sarcoma in a series of patients treated at a single institution: Local control directly impacts survival. Ann Surg 251:506-511.
18. Gustafson P. (1994). Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259:1-31.
19. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM. (2004). Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 91:242-247.
20. Kilvaer TK, Valkov A, Sorbye SW, Smeland E, Bremnes RM, Busund LT, Donnem T. (2011). Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med 9:104.
21. Kilvaer TK, Valkov A, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT. (2010). Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival. Sarcoma 2010:751304.
22. Kim HS, Han KH, Chung HH, Kim JW, Park NH, Song YS, Kang SB. (2010). Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison. Eur J Surg Oncol 36:691-698.
23. Kotzsch M, Magdolen V, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Eckert AW, Luther T, Baretton G, Wurl P, Taubert H. (2011). Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. BMC Cancer 11:273.
24. Lahat G, Zhang P, Zhu QS, Torres K, Ghadimi M, Smith KD, Wang WL, Lazar AJ, Lev D. (2011). The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): A tissue microarray study. Histopathology 59:556-561.
25. Lee YK, Park NH, Lee H. (2012). Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma. Int J Gynecol Cancer 22:434-441.
26. Lee CH, Roh JW, Choi JS, Kang S, Park IA, Chung HH, Jeon YT, Kim JW, Park NH, Kang SB, Song YS. (2011). Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 21:668-672.
27. Leung EYL, Scott HR, McMillan DC. (2012). Clinical Utility of the Pretreatment Glasgow Prognostic Score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol 7:655-662.
28. Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature 454:436-444.
29. Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K. (2011). D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma. BMC Musculoskelet Disord 12:250.
30. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A. (2012). Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer 118:1055-1061.
31. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K. (2012). miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. J Pathol 226:796-805.
32. Porrata LF, Markovic SN. (2010). Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol 1:29-34.
33. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC. (2011). An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. Br J Cancer 104:726-734.
34. Rot S, Taubert H, Bache M, Greither T, Wurl P, Eckert AW, Schubert J, Vordermark D, Kappler M. (2011). A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the risk of tumor-related death in soft-tissue sarcoma patients. BMC Cancer 11:429.
35. Shau HY, Kim A. (1988). Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 141:4395-4402.
36. Shaw CM, Grobmyer SR, Ucar DA, Cance WG, Reith JD, Hochwald SN. (2012). Elevated expression of IRS2 in the progression from neurofibroma to malignant peripheral nerve sheath tumor. Anticancer Res 32:439-443.
37. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H, Nagata M. (2010). High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13:170-176.
38. Shon W, Jenkins SM, Ross DT, Seitz RS, Beck RA, Ring BZ, Okuno SH, Gibson LE, Folpe AL. (2011). Angiosarcoma: A study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness. J Cutan Pathol 38:961-966.
39. Smeland E, Kilvaer TK, Sorbye S, Valkov A, Andersen S, Bremnes RM, Busund LT, Donnem T. (2012). Prognostic impacts of hypoxic markers in soft tissue sarcoma. Sarcoma 2012:541650.
40. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. (2011). Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 6:e14611.
41. Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. (2012). Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 12:5. 544 O. K. Idowu et al. Biomarkers
42. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M. (2009). Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45:1950-1958.
43. Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Busund LT. (2011). The prognostic impact of TGF-s1, fascin, NF-?B and PKC-? expression in soft tissue sarcomas. PLoS ONE 6:e17507.
44. Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT. (2011). The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Transl Med 9:200.
45. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181-184.
46. Zhao Y, Liao Q, Zhu Y, Long H. (2011). Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis. Clin Orthop Relat Res 469:3190-3199.